Download PDF
Semin Reprod Med 2022; 40(01/02): 032-041
DOI: 10.1055/s-0041-1736337
Review Article

Female Hyperandrogenism in Elite Sports and the Athletic Triad

Angelica Lindén Hirschberg 
1   Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
2   Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Essential hyperandrogenism seems to be overrepresented in female elite athletes. This applies to mild forms such as polycystic ovary syndrome, as well as rare differences/disorders of sex development (DSD). The reason is likely a selection bias since there is increasing evidence that androgens are beneficial for athletic performance by potent anabolic effects on muscle mass and bone mass, and stimulation of erythropoiesis. XY DSD may cause a greatly increased production of testosterone in the male range, that is, 10 to 20 times higher than the normal female range. The established regulations concerning the eligibility of female athletes with severe hyperandrogenism to compete in the female classification remain controversial. The most common cause of menstrual disorders in female athletes, however, is probably an acquired functional hypothalamic disturbance due to energy deficiency in relation to energy expenditure, which could lead to low bone mineral density and increased risk of injury. This condition is particularly common in endurance and esthetic sports, where a lean body composition is considered an advantage for physical performance. It is important to carefully evaluate endocrine disturbances and menstrual disorders in athletes since the management should be specific according to the underlying cause.

Keywords

differences of sex development - female athlete triad - functional hypothalamic amenorrhea - hyperandrogenism - polycystic ovary syndrome


Publication History

Article published online:
11 October 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Azziz R, Carmina E, Chen Z. et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016; 2: 16057
    CrossrefPubMedGoogle Scholar
  • 2 Handelsman DJ, Hirschberg AL, Bermon S. Circulating testosterone as the hormonal basis of sex differences in athletic performance. Endocr Rev 2018; 39 (05) 803-829
    CrossrefPubMedGoogle Scholar
  • 3 Hirschberg AL. Female hyperandrogenism and elite sport. Endocr Connect 2020; 9: R81-R92
    CrossrefPubMedGoogle Scholar
  • 4 Constantini NW, Warren MP. Menstrual dysfunction in swimmers: a distinct entity. J Clin Endocrinol Metab 1995; 80 (09) 2740-2744
    PubMedGoogle Scholar
  • 5 Rickenlund A, Carlström K, Ekblom B, Brismar TB, von Schoultz B, Hirschberg AL. Hyperandrogenicity is an alternative mechanism underlying oligomenorrhea or amenorrhea in female athletes and may improve physical performance. Fertil Steril 2003; 79 (04) 947-955
    CrossrefPubMedGoogle Scholar
  • 6 Rickenlund A, Thorén M, Carlström K, von Schoultz B, Hirschberg AL. Diurnal profiles of testosterone and pituitary hormones suggest different mechanisms for menstrual disturbances in endurance athletes. J Clin Endocrinol Metab 2004; 89 (02) 702-707
    CrossrefPubMedGoogle Scholar
  • 7 Hagmar M, Berglund B, Brismar K, Hirschberg AL. Hyperandrogenism may explain reproductive dysfunction in Olympic athletes. Med Sci Sports Exerc 2009; 41 (06) 1241-1248
    CrossrefPubMedGoogle Scholar
  • 8 Dadgostar H, Razi M, Aleyasin A, Alenabi T, Dahaghin S. The relation between athletic sports and prevalence of amenorrhea and oligomenorrhea in Iranian female athletes. Sports Med Arthrosc Rehabil Ther Technol 2009; 1 (01) 16
    PubMedGoogle Scholar
  • 9 Eliakim A, Marom N, Galitskaya L, Nemet D. Hyperandrogenism among elite adolescent female athletes. J Pediatr Endocrinol Metab 2010; 23 (08) 755-758
    CrossrefPubMedGoogle Scholar
  • 10 Coste O, Paris F, Galtier F, Letois F, Maïmoun L, Sultan C. Polycystic ovary-like syndrome in adolescent competitive swimmers. Fertil Steril 2011; 96 (04) 1037-1042
    CrossrefPubMedGoogle Scholar
  • 11 Javed A, Kashyap R, Lteif AN. Hyperandrogenism in female athletes with functional hypothalamic amenorrhea: a distinct phenotype. Int J Womens Health 2015; 7: 103-111
    PubMedGoogle Scholar
  • 12 Łagowska K, Kapczuk K. Testosterone concentrations in female athletes and ballet dancers with menstrual disorders. Eur J Sport Sci 2016; 16 (04) 490-497
    CrossrefPubMedGoogle Scholar
  • 13 Koltun KJ, Williams NI, Scheid JL, De Souza MJ. Discriminating hypothalamic oligomenorrhea/amenorrhea from hyperandrogenic oligomenorrhea/amenorrhea in exercising women. Appl Physiol Nutr Metab 2020; 45 (07) 707-714
    CrossrefPubMedGoogle Scholar
  • 14 Hirschberg AL. Polycystic ovary syndrome, obesity and reproductive implications. Womens Health (Lond) 2009; 5 (05) 529-540 , quiz 541–542
    CrossrefPubMedGoogle Scholar
  • 15 Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2019; 3: CD007506
    PubMedGoogle Scholar
  • 16 Kogure GS, Silva RC, Picchi Ramos FK. et al. Women with polycystic ovary syndrome have greater muscle strength irrespective of body composition. Gynecol Endocrinol 2015; 31 (03) 237-242
    CrossrefPubMedGoogle Scholar
  • 17 Kogure GS, Silva RC, Miranda-Furtado CL. et al. Hyperandrogenism enhances muscle strength after progressive resistance training, independent of body composition, in women with polycystic ovary syndrome. J Strength Cond Res 2018; 32 (09) 2642-2651
    CrossrefPubMedGoogle Scholar
  • 18 Kogure GS, Ribeiro VB, Gennaro FGO, Ferriani RA, Miranda-Furtado CL, Reis RMD. Physical performance regarding handgrip strength in women with polycystic ovary syndrome. Rev Bras Ginecol Obstet 2020; 42 (12) 811-819
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Caliskan Guzelce E, Eyupoglu D, Torgutalp S. et al. Is muscle mechanical function altered in polycystic ovary syndrome?. Arch Gynecol Obstet 2019; 300 (03) 771-776
    CrossrefPubMedGoogle Scholar
  • 20 Ginsburg GS, O'Toole M, Rimm E, Douglas PS, Rifai N. Gender differences in exercise-induced changes in sex hormone levels and lipid peroxidation in athletes participating in the Hawaii Ironman triathlon. Ginsburg-gender and exercise-induced lipid peroxidation. Clin Chim Acta 2001; 305 (1-2): 131-139
    CrossrefPubMedGoogle Scholar
  • 21 Berg U, Enqvist JK, Mattsson CM. et al. Lack of sex differences in the IGF-IGFBP response to ultra endurance exercise. Scand J Med Sci Sports 2008; 18 (06) 706-714
    CrossrefPubMedGoogle Scholar
  • 22 Li CY, Hsu G-S, Suzuki K, Ko MH, Fang SH. Salivary immuno factors, cortisol and testosterone responses in athletes of a competitive 5,000 m race. Chin J Physiol 2015; 58 (04) 263-269
    CrossrefPubMedGoogle Scholar
  • 23 Monje C, Rada I, Castro-Sepulveda M, Peñailillo L, Deldicque L, Zbinden-Foncea H. Effects of a high intensity interval session on mucosal immune function and salivary hormones in male and female endurance athletes. J Sports Sci Med 2020; 19 (02) 436-443
    PubMedGoogle Scholar
  • 24 Enea C, Boisseau N, Ottavy M. et al. Effects of menstrual cycle, oral contraception, and training on exercise-induced changes in circulating DHEA-sulphate and testosterone in young women. Eur J Appl Physiol 2009; 106 (03) 365-373
    CrossrefPubMedGoogle Scholar
  • 25 Edwards DA, Kurlander LS. Women's intercollegiate volleyball and tennis: effects of warm-up, competition, and practice on saliva levels of cortisol and testosterone. Horm Behav 2010; 58 (04) 606-613
    CrossrefPubMedGoogle Scholar
  • 26 O'Leary CB, Lehman C, Koltun K, Smith-Ryan A, Hackney AC. Response of testosterone to prolonged aerobic exercise during different phases of the menstrual cycle. Eur J Appl Physiol 2013; 113 (09) 2419-2424
    CrossrefPubMedGoogle Scholar
  • 27 Cook CJ, Crewther BT, Kilduff LP, Agnew LL, Fourie P, Serpell BG. Testosterone and dihydrotestosterone changes in male and female athletes relative to training status. Int J Sports Physiol Perform 2021; 4: 1-7
    PubMedGoogle Scholar
  • 28 Lee PA, Nordenström A, Houk CP. et al; Global DSD Update Consortium. Global disorders of sex development update since 2006: perceptions, approach and care. Horm Res Paediatr 2016; 85 (03) 158-180
    CrossrefPubMedGoogle Scholar
  • 29 Bermon S, Garnier PY, Hirschberg AL. et al. Serum androgen levels in elite female athletes. J Clin Endocrinol Metab 2014; 99 (11) 4328-4335
    CrossrefPubMedGoogle Scholar
  • 30 Karkazis K, Jordan-Young R, Davis G, Camporesi S. Out of bounds? A critique of the new policies on hyperandrogenism in elite female athletes. Am J Bioeth 2012; 12 (07) 3-16
    CrossrefPubMedGoogle Scholar
  • 31 Bermon S, Ritzén M, Hirschberg AL, Murray TH. Are the new policies on hyperandrogenism in elite female athletes really out of bounds? Response to “out of bounds? A critique of the new policies on hyperandrogenism in elite female athletes”. Am J Bioeth 2013; 13 (05) 63-65
    CrossrefPubMedGoogle Scholar
  • 32 Ritzén M, Ljungqvist A, Budgett R. et al. The regulations about eligibility for women with hyperandrogenism to compete in women's category are well founded. A rebuttal to the conclusions by Healy et al. Clin Endocrinol (Oxf) 2015; 82 (02) 307-308
    CrossrefPubMedGoogle Scholar
  • 33 Sonksen P, Ferguson-Smith MA, Bavington LD. et al. Medical and ethical concerns regarding women with hyperandrogenism and elite sport. J Clin Endocrinol Metab 2015; 100 (03) 825-827
    CrossrefPubMedGoogle Scholar
  • 34 Allen DB. Hormonal eligibility criteria for ‘includes females’ competition: a practical but problematic solution. Horm Res Paediatr 2016; 85 (04) 278-282
    CrossrefPubMedGoogle Scholar
  • 35 The International Associations of Athletics Federations. Eligibility regulations for the female classification (athletes with differences of sex development). Version 2.0. 2019. Accessed June 1, 2020 at: www.iaaf.org/about-iaaf/documents/rules-regulations
    PubMedGoogle Scholar
  • 36 Hirschberg AL. Hyperandrogenism in female athletes. J Clin Endocrinol Metab 2019; 104 (02) 503-505
    CrossrefPubMedGoogle Scholar
  • 37 Hamilton BR, Lima G, Barrett J. et al. Integrating transwomen and female athletes with differences of sex development (DSD) into elite competition: the FIMS 2021 consensus statement. Sports Med 2021; 51: 1401-1415
    CrossrefPubMedGoogle Scholar
  • 38 Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987; 8 (01) 1-28
    CrossrefPubMedGoogle Scholar
  • 39 Notelovitz M. Androgen effects on bone and muscle. Fertil Steril 2002; 77 (Suppl. 04) S34-S41
    CrossrefPubMedGoogle Scholar
  • 40 Croson R, Gneezy U. Gender differences in preferences. J Econ Lit 2009; 47: 448-474
    CrossrefPubMedGoogle Scholar
  • 41 Cardinale M, Stone MH. Is testosterone influencing explosive performance?. J Strength Cond Res 2006; 20 (01) 103-107
    PubMedGoogle Scholar
  • 42 Crewther BT, Christian C. Relationships between salivary testosterone and cortisol concentrations and training performance in Olympic weightlifters. J Sports Med Phys Fitness 2010; 50 (03) 371-375
    PubMedGoogle Scholar
  • 43 Bermon S, Garnier PY. Serum androgen levels and their relation to performance in track and field: mass spectrometry results from 2127 observations in male and female elite athletes. Br J Sports Med 2017; 51 (17) 1309-1314
    CrossrefPubMedGoogle Scholar
  • 44 Eklund E, Berglund B, Labrie F, Carlström K, Ekström L, Hirschberg AL. Serum androgen profile and physical performance in women Olympic athletes. Br J Sports Med 2017; 51 (17) 1301-1308
    CrossrefPubMedGoogle Scholar
  • 45 Bermon S. Androgens and athletic performance of elite female athletes. Curr Opin Endocrinol Diabetes Obes 2017; 24 (03) 246-251
    CrossrefPubMedGoogle Scholar
  • 46 Wood RI, Stanton SJ. Testosterone and sport: current perspectives. Horm Behav 2012; 61 (01) 147-155
    CrossrefPubMedGoogle Scholar
  • 47 Huang G, Basaria S, Travison TG. et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause 2014; 21 (06) 612-623
    CrossrefPubMedGoogle Scholar
  • 48 Hirschberg AL, Elings Knutsson J, Helge T. et al. Effects of moderately increased testosterone concentration on physical performance in young women: a double blind, randomised, placebo controlled study. Br J Sports Med 2020; 54 (10) 599-604
    CrossrefPubMedGoogle Scholar
  • 49 Wiik A, Lundberg TR, Rullman E. et al. Muscle strength, size, and composition following 12 months of gender-affirming treatment in transgender individuals. J Clin Endocrinol Metab 2020; 105 (03) e805-e813
    CrossrefPubMedGoogle Scholar
  • 50 Manning J, Kilduff L, Cook C, Crewther B, Fink B. Digit ratio (2D:4D): a biomarker for prenatal sex steroids and adult sex steroids in challenge situations. Front Endocrinol (Lausanne) 2014; 5: 9
    CrossrefPubMedGoogle Scholar
  • 51 Swift-Gallant A, Johnson BA, Di Rita V, Breedlove SM. Through a glass, darkly: human digit ratios reflect prenatal androgens, imperfectly. Horm Behav 2020; 120: 104686
    CrossrefPubMedGoogle Scholar
  • 52 Hönekopp J, Schuster M. A meta-analysis on 2D:4D and athletic prowess: substantial relationships but neither hand out-predicts the other. Personal Individual Diff 2010; 48: 4-10
    CrossrefPubMedGoogle Scholar
  • 53 Giffin NA, Kennedy RM, Jones ME, Barber CA. Varsity athletes have lower 2D:4D ratios than other university students. J Sports Sci 2012; 30 (02) 135-138
    CrossrefPubMedGoogle Scholar
  • 54 Bennett M, Manning JT, Cook CJ, Kilduff LP. Digit ratio (2D:4D) and performance in elite rugby players. J Sports Sci 2010; 28 (13) 1415-1421
    CrossrefPubMedGoogle Scholar
  • 55 Eklund E, Ekström L, Thörngren J-O, Ericsson M, Berglund B, Hirschberg AL. Digit ratio (2D:4D) and physical performance in female Olympic athletes. Front Endocrinol (Lausanne) 2020; 11: 292
    CrossrefPubMedGoogle Scholar
  • 56 Mountjoy M, Sundgot-Borgen J, Burke L. et al. The IOC consensus statement: beyond the Female Athlete Triad–Relative Energy Deficiency in Sport (RED-S). Br J Sports Med 2014; 48 (07) 491-497
    CrossrefPubMedGoogle Scholar
  • 57 Hagmar M, Hirschberg AL, Berglund L, Berglund B. Special attention to the weight-control strategies employed by Olympic athletes striving for leanness is required. Clin J Sport Med 2008; 18 (01) 5-9
    CrossrefPubMedGoogle Scholar
  • 58 Sundgot-Borgen J, Torstveit MK. Aspects of disordered eating continuum in elite high-intensity sports. Scand J Med Sci Sports 2010; 20 (Suppl. 02) 112-121
    CrossrefPubMedGoogle Scholar
  • 59 Elliott-Sale KJ, Tenforde AS, Parziale AL, Holtzman B, Ackerman KE. Endocrine effects of relative energy deficiency in sport. Int J Sport Nutr Exerc Metab 2018; 28 (04) 335-349
    CrossrefPubMedGoogle Scholar
  • 60 Loucks AB, Mortola JF, Girton L, Yen SS. Alterations in the hypothalamic-pituitary-ovarian and the hypothalamic-pituitary-adrenal axes in athletic women. J Clin Endocrinol Metab 1989; 68 (02) 402-411
    CrossrefPubMedGoogle Scholar
  • 61 Laughlin GA, Yen SS. Nutritional and endocrine-metabolic aberrations in amenorrheic athletes. J Clin Endocrinol Metab 1996; 81 (12) 4301-4309
    PubMedGoogle Scholar
  • 62 Rickenlund A, Thorén M, Nybacka A, Frystyk J, Hirschberg AL. Effects of oral contraceptives on diurnal profiles of insulin, insulin-like growth factor binding protein-1, growth hormone and cortisol in endurance athletes with menstrual disturbance. Hum Reprod 2010; 25 (01) 85-93
    CrossrefPubMedGoogle Scholar
  • 63 Ackerman KE, Slusarz K, Guereca G. et al. Higher ghrelin and lower leptin secretion are associated with lower LH secretion in young amenorrheic athletes compared with eumenorrheic athletes and controls. Am J Physiol Endocrinol Metab 2012; 302 (07) E800-E806
    CrossrefPubMedGoogle Scholar
  • 64 Loucks AB, Laughlin GA, Mortola JF, Girton L, Nelson JC, Yen SS. Hypothalamic-pituitary-thyroidal function in eumenorrheic and amenorrheic athletes. J Clin Endocrinol Metab 1992; 75 (02) 514-518
    PubMedGoogle Scholar
  • 65 Yeager KK, Agostini R, Nattiv A, Drinkwater B. The female athlete triad: disordered eating, amenorrhea, osteoporosis. Med Sci Sports Exerc 1993; 25 (07) 775-777
    CrossrefPubMedGoogle Scholar
  • 66 Nattiv A, Loucks AB, Manore MM, Sanborn CF, Sundgot-Borgen J, Warren MP. American College of Sports Medicine. American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc 2007; 39 (10) 1867-1882
    PubMedGoogle Scholar
  • 67 Skarakis NS, Mastorakos G, Georgopoulos N. et al. Energy deficiency, menstrual disorders, and low bone mineral density in female athletes: a systematic review. Hormones (Athens) 2021; 20 (03) 439-448
    CrossrefPubMedGoogle Scholar
  • 68 Mountjoy M, Sundgot-Borgen JK, Burke LM. et al. IOC consensus statement on relative energy deficiency in sport (RED-S): 2018 update. Br J Sports Med 2018; 52 (11) 687-697
    CrossrefPubMedGoogle Scholar
  • 69 Adams J, Franks S, Polson DW. et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985; 2 (8469-70): 1375-1379
    CrossrefPubMedGoogle Scholar
  • 70 Gordon CM, Ackerman KE, Berga SL. et al. Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2017; 102 (05) 1413-1439
    CrossrefPubMedGoogle Scholar
  • 71 Barrack MT, Gibbs JC, De Souza MJ. et al. Higher incidence of bone stress injuries with increasing female athlete triad-related risk factors: a prospective multisite study of exercising girls and women. Am J Sports Med 2014; 42 (04) 949-958
    CrossrefPubMedGoogle Scholar
  • 72 Łagowska K, Kapczuk K, Jeszka J. Nine-month nutritional intervention improves restoration of menses in young female athletes and ballet dancers. J Int Soc Sports Nutr 2014; 11 (01) 52
    CrossrefPubMedGoogle Scholar
  • 73 De Souza MJ, Nattiv A, Joy E. et al; Female Athlete Triad Coalition, American College of Sports Medicine, American Medical Society for Sports Medicine, American Bone Health Alliance. 2014 Female Athlete Triad Coalition consensus statement on treatment and return to play of the female athlete triad: 1st International Conference held in San Francisco, CA, May 2012, and 2nd International Conference held in Indianapolis, IN, May 2013. Clin J Sport Med 2014; 24 (02) 96-119
    CrossrefPubMedGoogle Scholar
  • 74 Misra M, Katzman D, Miller KK. et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 2011; 26 (10) 2430-2438
    CrossrefPubMedGoogle Scholar
  • 75 Rickenlund A, Eriksson MJ, Schenck-Gustafsson K, Hirschberg AL. Amenorrhea in female athletes is associated with endothelial dysfunction and unfavorable lipid profile. J Clin Endocrinol Metab 2005; 90 (03) 1354-1359
    CrossrefPubMedGoogle Scholar
  • 76 Teede HJ, Misso ML, Costello MF. et al; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018; 110 (03) 364-379
    CrossrefPubMedGoogle Scholar
  • 77 Stepto NK, Patten RK, Tassone EC. et al. Exercise recommendations for women with polycystic ovary syndrome: Is the evidence enough?. Sports Med 2019; 49 (08) 1143-1157
    CrossrefPubMedGoogle Scholar
  • 78 Rickenlund A, Carlström K, Ekblom B, Brismar TB, Von Schoultz B, Hirschberg AL. Effects of oral contraceptives on body composition and physical performance in female athletes. J Clin Endocrinol Metab 2004; 89 (09) 4364-4370
    CrossrefPubMedGoogle Scholar
  • 79 Elliott-Sale KJ, McNulty KL, Ansdell P. et al. The effects of oral contraceptives on exercise performance in women: a systematic review and meta-analysis. Sports Med 2020; 50 (10) 1785-1812
    CrossrefPubMedGoogle Scholar
  • 80 Cools M, Nordenström A, Robeva R. et al; COST Action BM1303 working group 1. Caring for individuals with a difference of sex development (DSD): a Consensus Statement. Nat Rev Endocrinol 2018; 14 (07) 415-429
    CrossrefPubMedGoogle Scholar